Selective androgen receptor modulator
Ostarine (MK-2866)
Ostarine (MK-2866) after one dose: 50% at ~24 h, 25% at 48 h, 12.5% at 72 h.
Drawn from the half-life in the app's model, ~24 h. The model's figures
- Compound
- Ostarine (MK-2866)
- Symbol
- OST
- Family
- SARMs
- Parts
- 13
- References
- 20
- Checked
- Last reviewed . Sources are listed below.
Overview
Ostarine, also called enobosarm, MK-2866 and GTx-024, is an oral, nonsteroidal selective androgen receptor modulator (SARM).3,4,5 Dalton and colleagues, all eight listed as employees of GTx, Inc., describe it as a compound with "tissue-selective anabolic effects in muscle and bone, while sparing other androgenic tissue related to hair growth in women and prostate effects in men".4
FDA states that SARMs "are not FDA approved" and "cannot be legally marketed in the U.S. as a dietary supplement or drug at this time".2 Its December 2025 warning letter to a seller names "Ostarine MK-2866" among products marketed as SARMs that FDA calls "unapproved new drugs".6 The WADA 2026 Prohibited List names enobosarm (ostarine) in section S1.2, other anabolic agents.7
Trials cover healthy older adults (Dalton and colleagues, 2011), people with cancer and weight loss (Dobs and colleagues, 2013), women with breast cancer (Palmieri and colleagues, 2024) and, in registry results, lung cancer (two phase 3 trials).4,5,8,9,10 Case reports describe liver injury in men who used ostarine or a product containing it.3,11,12
How it works
Sources in this part
In their 2011 trial in healthy volunteers, "GTx-024 did not have effects on sebum production or hair growth in women", and the paper's text reports that in men there were "no statistically significant differences from placebo" in free testosterone, DHT, estradiol, FSH or LH at any dose (its Table 5 lists exceptions for free testosterone, see Bloodwork and markers).4 The same trial reported lower sex hormone-binding globulin and total testosterone in men than on placebo, and in women lower SHBG at 1 and 3 mg (-39.3 and -36.4 nmol/L, P below 0.001) and lower LH and FSH at 3 mg, which the authors call "not clinically significant".4 In the 2013 cancer trial of Dobs and colleagues, "there were no significant differences within the enobosarm and placebo groups in change in hair growth in women", nor in serum prostate-specific antigen in men.5
In animals, cells and human urine
In rats given radiolabelled GTx-024 (authors at GTx, Inc.), "Absorption of GTx-024 was rapid and complete, with high oral bioavailability", and the mean elimination half-life of the radioactivity was 0.6 h in male and 16.4 h in female rats.13 Taoussi and colleagues incubated ostarine with human hepatocytes, screened urine from six ostarine-positive cases, identified ten metabolites and suggested that "The production of cyanophenol-sulfate might participate in the mechanism of ostarine liver toxicity".14 The authors write that the toxicological relevance of the potential in vivo production of cyanophenol-sulfate needs further investigation, and the same compound also appeared in blank urine, so it is not clear whether it comes only from the body or also from ostarine metabolism.14
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~24 h
- Bioavailability
- 95%
- Typical dose
- 10–25 mg/day
- Route
- Oral
- Time to peak
- ~2 h
The app lists the half-life of ostarine as about 24 hours. The EMERALD trial protocol (sponsor: University of Liverpool; study drug developer: GTx, Inc.) summarises two phase 1 studies of enobosarm, citing Jones and colleagues, Drugs of the Future, 2013, and GTx, 2015.1 After a single oral dose of 1 mg to 100 mg in 48 healthy men, "the half-life of enobosarm was between 21 and 24 hours".1 In the 14-day multiple-dose study, "the terminal half-life ranged from 14 to 21 hours", maximum plasma concentrations "were achieved at approximately one hour", and "steady state was reached prior to Day 6".1
| Parameter | Value | Note |
|---|---|---|
| Half-life | ~24 hours | App's figure; the phase 1 summary gives 21 to 24 hours after a single dose and a terminal half-life of 14 to 21 hours after 14 days of dosing.1 |
| Bioavailability (oral) | ~95% | App's figure; no human percentage is given in the sources listed here, and in rats (authors at GTx, Inc.) absorption was "rapid and complete, with high oral bioavailability".13 |
| Time to peak | ~2 hours | App's figure; the phase 1 summary gives about one hour after a dose in the 14-day study.1 |
| Interaction with rifampin | GTx-024 AUC∞ 43% lower with rifampin than without | Open-label phase 1 study; rifampin lowered the maximal plasma concentration of GTx-024 by 23%, and the paper's summary gives no dose, number of people or length.15 |
The chart below uses the app's half-life of 24 hours and time to peak of 2 hours, with once daily as in the phase 2 trials of Dalton and colleagues and Dobs and colleagues.4,5
Level over 1 weeks
Level, as a share of the peak after one 3 mg dose
As studied: once daily4.
An illustration from a pharmacokinetic model using a half-life of 24 hours. It is not a measured level or a suggested dose.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Dalton and colleagues, 20114 | Randomised, double-blind, placebo-controlled phase 24 | 120 healthy men over 60 and postmenopausal women; 115 completed4 | 0.1, 0.3, 1 or 3 mg once daily, 86 days4 | Lean body mass +1.3 kg against placebo at 3 mg (P < 0.001); +0.7 kg at 1 mg, not significant (P = 0.055); HDL 27% lower at 3 mg4 |
| Dobs and colleagues, 20135 | Randomised (1:1:1), double-blind, placebo-controlled phase 25 | 159 men over 45 and postmenopausal women with cancer and weight loss; 100 in the efficacy analysis5 | 1 mg or 3 mg once daily, or placebo, up to 113 days5 | Median lean body mass change from baseline +1.5 kg at 1 mg (p=0.0012), +1.0 kg at 3 mg (p=0.046) and +0.02 kg on placebo (p=0.88)5 |
| POWER 1, registry results, 20169 | Randomised, double-blind, placebo-controlled phase 3; platinum plus taxane chemotherapy9 | 321 enrolled with stage III or IV non-small cell lung cancer9 | 3 mg once daily for 147 days, as designed17 | Day 84 responders (lean body mass change of 0% or more; stair climb power gain of 10% or more): lean body mass 41.9% (95% CI 34.1 to 49.9) against 30.4% (23.4 to 38.2) on placebo; stair climb power 29.4% (22.4 to 37.1) against 24.2% (17.8 to 31.6); intervals overlap, no between-group test listed9,17 |
| POWER 2, registry results, 202010 | Randomised, double-blind, placebo-controlled phase 3; platinum plus non-taxane chemotherapy10 | 330 enrolled with stage III or IV non-small cell lung cancer10 | 3 mg once daily for 147 days, as designed17 | Day 84 responders (lean body mass change of 0% or more; stair climb power gain of 10% or more): lean body mass 46.5% (95% CI 38.6 to 54.6) against 37.9% (30.4 to 45.9) on placebo; stair climb power 19.5% (13.6 to 26.5) against 24.8% (18.4 to 32.3); intervals overlap, no between-group test listed10,17 |
| Palmieri and colleagues, 20248 | Randomised, open-label phase 2, 35 centres in nine countries8 | 136 postmenopausal women with ER-positive, HER2-negative advanced breast cancer; 102 AR-positive and evaluable8 | 9 mg or 18 mg daily; median follow-up 7.5 months8 | Clinical benefit at 24 weeks: 32% (95% CI 20 to 47) at 9 mg and 29% (17 to 43) at 18 mg; grade 3 or 4 drug-related adverse events in 8% and 16%8 |
| Yuan and colleagues, 202118 | Open-label phase 2, stopped early when GTx-024 supply was withdrawn18 | 18 enrolled and 16 evaluable, with androgen receptor-positive metastatic triple-negative breast cancer18 | Enobosarm 18 mg daily with pembrolizumab 200 mg intravenously every 3 weeks18 | Response rate 13% (2 of 16); 12 of 16 progressive disease; clinical benefit rate 25% at 16 weeks; progression-free survival 2.6 months (95% CI 1.9 to 3.1); overall survival 25.5 months (95% CI 10.4 to not reached); three grade 3 events (dry skin, diarrhoea, musculoskeletal ache)18 |
PubMed, searched on 16 November 2026, returned 109 records; none of their titles reports the results of the POWER trials. ClinicalTrials.gov, searched the same day, returned 17 studies of enobosarm, including phase 2 trials in stress urinary incontinence (such as NCT03241342, 491 enrolled, completed) and phase 3 trials in lung cancer and breast cancer; the list marks NCT04869943 as terminated.
Deeper analysis: phase 2 trial in healthy volunteers (Dalton and colleagues, 2011)
Who and how. Dalton and colleagues (first author at GTx, Inc., Memphis) reported in Journal of Cachexia, Sarcopenia and Muscle a trial at phase 1 units in the UK and Germany, with 24 people in each of five groups (placebo and four doses) and equal numbers of men and women, and a primary endpoint of total lean body mass on dual energy X-ray absorptiometry.4
Sponsor and author ties. The trial material was provided by GTx, Inc., and the paper states that the eight authors "are employees of and have stock and stock options with GTx, Inc.".4
Findings. At 3 mg, lean body mass rose by an average of 1.3 kg more than on placebo and stair climb power improved (P = 0.013 in the text, 0.049 in Table 2).4 At 0.1 mg stair climb power fell by 16.68 W against a rise of 20.35 W on placebo (P = 0.012).4 At 1 mg the lean mass change was not statistically significant, and the paper reports no difference in bone mineral density (data not shown).4 "The incidence of adverse events was similar among groups", "No SAEs were reported during the study", and five people stopped early, one of them for ALT elevation at 3 mg.4
Authors' conclusion and limits. The authors concluded that GTx-024 "was well tolerated in elderly men and postmenopausal women", and wrote that bone density changes "were not necessarily expected as the treatment period was likely too short to detect a benefit"; the paper contains no separate limitations paragraph, but its Methods state that the analysis was in the 115 who completed the study and that "P values reported are two sided and are unadjusted for multiple comparisons".4
Deeper analysis: phase 2 trial in people with cancer (Dobs and colleagues, 2013)
Who and how. Dobs (Johns Hopkins University) and colleagues reported in The Lancet Oncology a trial at oncology clinics in the US and Argentina in which "The sponsor, study personnel, and participants were masked to assignment".5 Efficacy was analysed only in an evaluable population of 100 of the 159 people.5
Sponsor and author ties. The paper states "FUNDING: GTx" and "GTx sponsored designing of the study and medical writing support"; four authors "are employees of and have stock and stock options with GTx", and five "received research funds from GTx for this study".5
Findings. Each group was compared with its own baseline, and mean stair climb power improved by 18.0% at 1 mg and 21.7% at 3 mg against 4.8% on placebo, with no significant difference in hand grip strength, ECOG status or frailty status.5 Of 159 people, 53 discontinued treatment (18 of 159, 11%, because of an adverse event), serious adverse events occurred in 26%, 28% and 33% of the 1 mg, 3 mg and placebo groups, 27 people died (placebo 11, 1 mg 8, 3 mg 8), and "No serious or life-threatening adverse events were deemed to be related to study drug".5 Treatment-related adverse events were more common at 3 mg (15 of 54, 28%) than at 1 mg (7 of 53, 13%) or on placebo (8 of 52, 15%), and life-threatening adverse events occurred in 11%, 7% and 15% of the 1 mg, 3 mg and placebo groups.5 Three people at 3 mg had "transient (returning to normal while still on drug) alanine aminotransferase increases that were two to three times the upper limit of normal", one person each at 3 mg and on placebo had a transient rise to more than three times the limit, and none rose above four times.5
Authors' limits. The authors wrote that "the small sample size and heterogeneity of cancer types studied could be deemed potential limitations" and that "Another limitation is the number of missing patients in the efficacy analysis".5 The trial "was not powered to assess survival".5
Deeper analysis: phase 3 POWER trials (registry results)
Design. Crawford and colleagues (first author at Duke University) described two identically designed trials in non-small-cell lung cancer, with placebo or enobosarm 3 mg once daily for 147 days and co-primary endpoints at day 84.17
Sponsor and ties. The design paper states "This work was supported by GTx, Inc." and that Crawford "received research funding through a grant from GTx, Inc. to Duke University to conduct the trials in this article".17 The paper adds that "The trial herein described was initiated, designed, and funded by GTx, Inc.", and three coauthors are listed as employees of GTx, Inc. who own stock and have stock options, one of them with a patent application pending.17 Coauthor Dalton, a former GTx employee and "currently a paid consultant to GTx, Inc.", has "US and international patents on enobosarm" and receives royalties paid by GTx.17
Findings. The responder percentages and their 95% confidence intervals are in the table above, the intervals overlap within each pair and no between-group test is listed, and in POWER 2 the placebo figure for stair climb power was higher.9,10 Serious adverse events were listed for 56 of 160 against 60 of 161 in POWER 1 and 109 of 165 against 113 of 165 in POWER 2, and the POWER 2 participant flow lists 19 deaths on enobosarm and 18 on placebo.9,10 The registry's terms record a restrictive agreement that gives the sponsor an advance copy of any results communication, with the right to request changes and a delay.9,10
Deeper analysis: phase 2 trial in breast cancer (Palmieri and colleagues, 2024)
Who and how. Palmieri (Clatterbridge Cancer Centre and University of Liverpool) and colleagues reported in The Lancet Oncology a randomised comparison of two daily doses without a placebo arm, in previously treated postmenopausal women, with clinical benefit rate at 24 weeks in the 102 women with centrally confirmed AR-positive disease as the primary endpoint.8
Sponsor and author ties. The record states "FUNDING: GTx", and the disclosures include "PC reports research support from GTx" and "BO reports funding from GTx".8
Findings. The authors concluded that "Enobosarm has anti-tumour activity in patients with ER-positive, HER2-negative advanced breast cancer".8 Grade 3 or 4 drug-related adverse events occurred in 8% (6 of 75) at 9 mg and 16% (10 of 61) at 18 mg, most often increased hepatic transaminases, hypercalcaemia and fatigue, and four deaths were "deemed unrelated to the study drug".8 The PubMed record states no limitations of its own.
Doses reported in studies
| Source | Dose | Frequency | Length |
|---|---|---|---|
| Dalton and colleagues, 2011 (healthy volunteers)4 | 0.1, 0.3, 1 or 3 mg4 | Once daily4 | 86 days4 |
| Dobs and colleagues, 2013 (cancer)5 | 1 mg or 3 mg5 | Once daily5 | Up to 113 days5 |
| POWER trials, as designed (lung cancer)17 | 3 mg17 | Once daily17 | 147 days17 |
| Palmieri and colleagues, 2024 (breast cancer)8 | 9 mg or 18 mg8 | Daily8 | Median follow-up 7.5 months8 |
| Yuan and colleagues, 2021 (breast cancer)18 | 18 mg, with pembrolizumab 200 mg intravenously18 | Daily; pembrolizumab every 3 weeks18 | Median follow-up 24.9 months18 |
| Phase 1 studies (healthy young men; 3 and 30 mg also in elderly men with truncal obesity), EMERALD summary1 | 1 mg to 100 mg once; 1, 3, 10 or 30 mg for 14 days1 | Single dose; daily1 | 1 day; 14 days1 |
The app's typical dose for ostarine is 10 to 25 mg a day. Doses of 10 mg or more appear in the sources listed here as the phase 1 doses (10, 30 and up to 100 mg) and as 18 mg in the two phase 2 breast cancer trials; the other trials gave 0.1 to 3 mg a day, and no trial listed here names a 25 mg dose.1,8,18,4,5,17
Side effects reported
In the 2011 phase 2 trial, adverse events were similar between groups, ALT above the upper limit of normal was recorded in eight subjects, and an ALT increase was reported as an adverse event in 5 of 24 (20.8%) at 3 mg against none on placebo.4 The paper adds that "No significant increases in total bilirubin, GGT, or alkaline phosphatase were observed at any GTx-024 dose", and that small increases in hemoglobin and hematocrit occurred at 3 mg.4 In the EMERALD protocol's summary of the 14-day phase 1 study, "The most common treatment emergent adverse effect was elevated ALT outside the normal range".1
Case reports: liver
Weinblatt and Roy (Journal of Medical Cases, 2022) describe a 31-year-old man whose over-the-counter muscle-building supplement contained enobosarm and, the authors write, "no other ingredients"; ALT was 346 U/L and AST 110 U/L at presentation, and 25 U/L and 18 U/L at 10 months.3 Bedi and colleagues (ACG Case Reports Journal, 2021) describe a man in his early 40s who used enobosarm for 2 months without medical supervision, with a biopsy showing "moderate to severe cholestasis" and a peak bilirubin of 0.735 mmol/L.11 Mertens and colleagues (Zeitschrift für Gastroenterologie, 2024) describe a 24-year-old man with total bilirubin above 30 mg/dL who needed albumin dialysis and reached normal bilirubin "as late as six months after first intake of the compound".12 Koller and colleagues (World Journal of Clinical Cases, 2021) describe two men aged 19 and 28 who used ligandrol and/or ostarine and then post-cycle therapy substances, and write that "The off target effects of SARMs were likely idiosyncratic" while highlighting "the yet unrecognized effects of other toxic substances used for PCT".19
Class statements from FDA
FDA's December 2025 warning letter states that "Life-threatening reactions, including liver toxicity, have occurred in people taking products containing SARMs" and that "SARMs also have the potential to increase the risk of heart attack and stroke".6 Its consumer update says that "Studies and reports show SARMs are associated with serious or life-threatening health problems", and lists liver injury and acute liver failure among them.2
Bloodwork and markers
Sources in this part
The app lists total testosterone, lipids and liver enzymes as markers for ostarine. In the 2011 trial, men on 1 mg and 3 mg had lower total testosterone than on placebo (-6.4 ± 1.1 and -7.4 ± 1.0 nmol/L), with the paper's text reporting no significant difference in free testosterone at any dose, although its Table 5 lists differences from placebo at 0.1 mg (P = 0.003) and 0.3 mg (P below 0.001) with baselines that differ between groups.4 The EMERALD summary of the 14-day phase 1 study also reports a dose-dependent reduction in sex hormone-binding globulin, with a reduction in total testosterone and no clinically significant change in free testosterone, citing GTx, 2015.1 HDL fell by 17% at 1 mg and 27% at 3 mg, total cholesterol was lower at 0.3, 1 and 3 mg, and "No significant effect on low-density lipoprotein (LDL) was observed among treatment groups".4
Regulatory and anti-doping status
Sources in this part
The WADA 2026 Prohibited List, in effect from 1 January 2026, names enobosarm (ostarine) in section S1.2, other anabolic agents, among "selective androgen receptor modulators [SARMs, e.g. andarine, enobosarm (ostarine), LGD-4033 (ligandrol), RAD140, S-23 and YK-11]".7
Van Wagoner and colleagues (JAMA, 2017) analysed 44 products sold online as SARMs and reported that 23 (52%) contained one or more SARMs (Ostarine, LGD-4033 or Andarine), 17 (39%) contained another unapproved drug, and the amount matched the label in 18 (41%).20 The authors called it a "limited investigation".20 The sources listed here do not state ostarine's legal status in Australia.
What is not known
Sources in this part
The sources listed here give no human oral bioavailability percentage, and the half-life and time-to-peak figures come from a protocol's summary of phase 1 reports that are not listed here.1 The 2016 design paper stated that "Full results from these studies will soon be published", and the POWER results in the sources listed here are the registry's, with no peer-reviewed report among the PubMed titles of 16 November 2026.17 The case reports describe one or two people each and give no frequency of liver injury.12
Frequently asked questions
Sources in this part
- 1University of Liverpool, 2021
- 2US Food and Drug Administration
- 3Weinblatt et al., 2022
- 4Dalton et al., 2011
- 5Dobs et al., 2013
- 6US Food and Drug Administration, 2025
- 7World Anti-Doping Agency, 2026
- 8Palmieri et al., 2024
- 9GTx
- 10GTx
- 11Bedi et al., 2021
- 13Kim et al., 2013
- 16Walpurgis et al., 2020
- 17Crawford et al., 2016
- 18Yuan et al., 2021
What is the half-life of ostarine?
In phase 1 studies summarised in the EMERALD trial protocol, the half-life of enobosarm (ostarine) was between 21 and 24 hours after a single dose and 14 to 21 hours after 14 days of dosing.1 The app's figure is about 24 hours.
What is ostarine?
Is ostarine FDA approved?
Is ostarine banned by WADA?
Yes: the WADA 2026 Prohibited List names enobosarm (ostarine) in section S1.2, other anabolic agents, under "SUBSTANCES & METHODS PROHIBITED AT ALL TIMES".7
Does ostarine cause liver problems?
Case reports describe liver injury in men who used ostarine or a product containing it.3,11 In the 2011 trial, transient ALT rises above the upper limit of normal were reported in eight subjects, and one person stopped for ALT 4.2 times the upper limit.4 Palmieri and colleagues reported grade 3 or 4 increased hepatic transaminases in 4% at 9 mg and 3% at 18 mg, and the EMERALD summary of the 14-day phase 1 study reports a dose-dependent rise in mean ALT, with a notable AST rise at 30 mg.8,1
What did the trials of ostarine find?
In 120 healthy men over 60 and postmenopausal women, 3 mg a day for 86 days raised lean body mass by 1.3 kg more than placebo (P < 0.001), while 1 mg did not differ significantly (P = 0.055).4 In the two GTx-funded phase 3 lung cancer trials, day 84 responders were 41.9% against 30.4% and 46.5% against 37.9% on placebo for no loss of lean body mass, and 29.4% against 24.2% and 19.5% against 24.8% for a stair climb power gain of 10% or more.9,10,17
What doses of ostarine were used in studies?
The phase 2 trials in healthy volunteers and in people with cancer and weight loss gave 0.1 to 3 mg once daily, the POWER trials were designed for 3 mg once daily, and the phase 2 breast cancer trials gave 9 mg or 18 mg daily (Yuan: 18 mg with pembrolizumab).4,5,17,8,18 The app's typical dose is 10 to 25 mg a day.
Does ostarine lower testosterone?
In the 2011 trial, men on 1 mg and 3 mg had lower total testosterone than on placebo, by 6.4 and 7.4 nmol/L, and the paper's text reports no significant difference in free testosterone at any dose, although its Table 5 lists differences at 0.1 and 0.3 mg.4
How long can ostarine be detected in urine?
Walpurgis and colleagues reported that detection times rose with the dose given (1, 10 and 50 μg were tested) and that "a single oral dose of as little as 1 μg can be detected for up to 9 (5) days by monitoring ostarine (glucuronide)", with high variation between people; the paper's summary does not explain the 5 in brackets.16
What is the bioavailability of ostarine?
The app's figure is about 95%, and the sources listed here give no human percentage; in rats (authors at GTx, Inc.), absorption was "rapid and complete, with high oral bioavailability".13
Guides, tools and comparisons
References
- University of Liverpool. EMERALD: a window of opportunity study to assess the biological effect of enobosarm in oestrogen receptor positive, androgen receptor positive early breast cancer. Study protocol, version 6.0, 17 May 2021. ISRCTN12213700. ISRCTN12213700 protocol
- US Food and Drug Administration. FDA Warns of Use of Selective Androgen Receptor Modulators (SARMs) Among Teens, Young Adults. Consumer update. FDA consumer update
- Weinblatt D, Roy S. Drug-Induced Liver Injury Secondary to Enobosarm: A Selective Androgen Receptor Modulator. J Med Cases 2022. PMC9119364
- Dalton JT, Barnette KG, Bohl CE, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2011. PMC3177038
- Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013. PMC4898053
- US Food and Drug Administration. Warning letter 719257 to Dynamic Health Group dba SARMS AMERICA, 12 December 2025. FDA warning letter
- World Anti-Doping Agency. The 2026 Prohibited List. In effect 1 January 2026. WADA 2026 Prohibited List
- Palmieri C, Linden H, Birrell SN, et al. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol 2024. PMID 38342115
- GTx. Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) (POWER 1). ClinicalTrials.gov NCT01355484. NCT01355484
- GTx. Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum (POWER 2). ClinicalTrials.gov NCT01355497. NCT01355497
- Bedi H, Hammond C, Sanders D, et al. Drug-Induced Liver Injury From Enobosarm (Ostarine), a Selective Androgen Receptor Modulator. ACG Case Rep J 2021. PMC8337042
- Mertens JE, Bömmer MTC, Regier MB, et al. Liver Injury after Selective Androgen Receptor Modulator Intake: A Case Report and Review of the Literature. Z Gastroenterol 2024. PMID 37871633
- Kim J, Wang R, Veverka KA, Dalton JT. Absorption, distribution, metabolism and excretion of the novel SARM GTx-024 [(S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide] in rats. Xenobiotica 2013. PMID 24074268
- Taoussi O, Bambagiotti G, Gameli PS, et al. In Vitro and In Vivo Human Metabolism of Ostarine, a Selective Androgen Receptor Modulator and Doping Agent. Int J Mol Sci 2024. PMC11277069
- Coss CC, Jones A, Dalton JT. Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024 (enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin. Invest New Drugs 2016. PMID 27105861
- Walpurgis K, Rubio A, Wagener F, et al. Elimination profiles of microdosed ostarine mimicking contaminated products ingestion. Drug Test Anal 2020. PMID 32959982
- Crawford J, Prado CM, Johnston MA, et al. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr Oncol Rep 2016. PMC4853438
- Yuan Y, Lee JS, Yost SE, et al. A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. Oncologist 2021. PMID 33141975
- Koller T, Vrbova P, Meciarova I, et al. Liver injury associated with the use of selective androgen receptor modulators and post-cycle therapy: Two case reports and literature review. World J Clin Cases 2021. PMC8180234
- Van Wagoner RM, Eichner A, Bhasin S, et al. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA 2017. PMID 29183075